Summary of Key Information:

Reporting Period: Quarter and Half Year ended September 30, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results

Audit Opinion:

Limited Review Report issued by Brahmayya & Co., Chartered Accountants. No qualified or modified opinion noted.

Key Financial Highlights [All amounts in ₹ Crores]:

Standalone Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹241.88 (Q2 FY26: ₹175.18, +38.1% YoY)
  • Total Income: ₹292.92 (Q2 FY26: ₹234.40, +25.0% YoY)
  • Net Profit: ₹130.51 (Q2 FY26: ₹102.59, +27.2% YoY)
  • EPS (Basic): ₹17.17 (Q2 FY26: ₹13.50)

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹444.83 (H1 FY26: ₹357.75, +24.3% YoY)
  • Total Income: ₹558.66 (H1 FY26: ₹449.00, +24.4% YoY)
  • Net Profit: ₹250.89 (H1 FY26: ₹188.48, +33.1% YoY)
  • EPS (Basic): ₹33.01 (H1 FY26: ₹24.80)
  • Other Equity: ₹2,226.09 (March 31, 2026: ₹2,035.30)
  • Cash and Cash Equivalents: ₹32.83 (March 31, 2026: ₹44.09)
  • Total Debt: Not specified (Finance costs minimal at ₹0.11 for H1 FY27)

Consolidated Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: ₹629.84 (Q2 FY26: ₹534.04, +17.9% YoY)
  • Total Income: ₹663.13 (Q2 FY26: ₹564.41, +17.5% YoY)
  • EBITDA: ₹256.51 (Q2 FY26: ₹219.54, +16.8% YoY)
  • Net Profit: ₹182.35 (Q2 FY26: ₹160.23, +13.8% YoY)
  • EPS (Basic): ₹23.44 (Q2 FY26: ₹20.32)

Half Year Ended September 30, 2026:

  • Revenue from Operations: ₹1,240.20 (H1 FY26: ₹1,044.26, +18.8% YoY)
  • Total Income: ₹1,307.04 (H1 FY26: ₹1,097.77, +19.1% YoY)
  • EBITDA: ₹503.54 (H1 FY26: ₹420.44, +19.8% YoY)
  • Net Profit: ₹361.44 (H1 FY26: ₹310.99, +16.2% YoY)
  • EPS (Basic): ₹46.71 (H1 FY26: ₹40.42)
  • Other Equity: ₹3,812.67 (excluding non-controlling interest)
  • Cash and Cash Equivalents: ₹86.62
  • Total Liquid Assets: ₹2,967 Crores (as per press release)
  • Free Cash Reserves: ₹1,534 Crores (as per press release)

Segment-wise Performance:

The Group has two geographical reportable segments:

Rest of the World Segment (Q2 FY27):

  • Segment Revenue: ₹500.12
  • Segment Profit (PBT): ₹183.22

USA Segment (Q2 FY27):

  • Segment Revenue: ₹129.72
  • Segment Profit (PBT): ₹16.32

H1 FY27 Geographical Revenue Composition:

  • Emerging Markets (Latin America & Africa): 79%
  • US Market: 21%

Corporate Actions:

  • Final dividend of ₹4.00 per equity share (200%) for FY 2025-26 approved by shareholders on September 25, 2026
  • Total dividend for FY 2025-26: ₹8.00 per equity share (400% of face value ₹2 each)
  • Dividend paid to shareholders on October 7, 2026

Other Significant Information:

Business Highlights - Emerging Markets:

  • Won tenders worth $5.3 million in Central America (70% oncology products)
  • Won new tenders worth $5 million in Chile
  • Started commercial sales of oncology products in Mexico
  • Received 4 new product approvals in Mexico with 13 under review
  • Oncology facility in Kakkalur completed exhibit batches for 4 injectables and OSD products
  • API unit at Vizag received commercial license
  • Oncology API unit in Thervoy, TN to be completed by CY27
  • OSD and Dermatology facility expansion in Pondy underway
  • Amaris Clinical expansion to increase capacity to 120 beds by end FY27

Business Highlights - US & Regulated Markets:

  • Caplin Steriles Limited (CSL) filed 120+ products (75 approved) in non-US markets
  • Plans to file 60+ more products in next 18 months
  • Launched 40 products in US with plans for 10 more in FY28
  • Completed exhibit batches for 2 Pre-Filled Syringe products
  • COL-II facility construction to be completed by August 2027
  • Caplin Steriles USA Inc (CSU) H1 sales surpassed FY26 full year sales
  • 5,600+ unique customers in US, 20% increase over FY26
  • Average sales per day increased from $32,936 in FY26 to $61,330

Strategic Growth Initiatives:

  • Enhanced Capex budget of approximately ₹1,000+ Crores
  • 50% of projects nearing completion
  • Investments to be completed over next 2 years
  • Projects to be commercialized within 1 year from completion
  • Capex to be financed solely through internal accruals

Entities Included in Consolidation:

The consolidated results include:

  • Caplin Point Laboratories Limited (Holding Company)
  • Caplin Steriles Limited, India
  • Argus Salud Pharma LLP, India
  • Caplin One Labs Limited, India
  • Caplin Point Far East Limited, Hong Kong
  • Caplin Point (S) Pte. Ltd, Singapore
  • 8 step-down subsidiaries in Latin America
  • Caplin Steriles USA Inc., USA
  • Associate: Sunsole Solar Private Limited, India